The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Liver Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Liver Neoplasms


Psychiatry related information on Liver Neoplasms


High impact information on Liver Neoplasms


Chemical compound and disease context of Liver Neoplasms


Biological context of Liver Neoplasms


Anatomical context of Liver Neoplasms


Gene context of Liver Neoplasms

  • The Cul4A gene is amplified in human breast and liver cancers, and loss-of-function of Cul4 results in the accumulation of the replication licensing factor CDT1 in Caenorhabditis elegans embryos and ultraviolet (UV)-irradiated human cells [26].
  • BACKGROUND & AIMS: Wnt/beta-catenin activation is observed in normal liver development, regeneration, and liver cancer [27].
  • We showed a switch from MAT1A to MAT2A gene expression in human liver cancer cells that may offer a growth advantage [28].
  • Genotypic and phenotypic characterization of a putative tumor susceptibility gene, GNMT, in liver cancer [29].
  • In conclusion, in liver cancers ADAM9 and ADAM12 expression is associated with tumor aggressiveness and progression [30].

Analytical, diagnostic and therapeutic context of Liver Neoplasms


  1. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. Eriksson, S., Carlson, J., Velez, R. N. Engl. J. Med. (1986) [Pubmed]
  2. Modification of diethylnitrosamine liver carcinogenesis with phenobarbital but not with immunosuppression. Weisburger, J.H., Madison, R.M., Ward, J.M., Viguera, C., Weisburger, E.K. J. Natl. Cancer Inst. (1975) [Pubmed]
  3. A monoclonal antibody against gamma-glutamyltransferase from human primary hepatoma: its use in enzyme-linked immunosorbent assay of sera of cancer patients. Taniguchi, N., House, S., Kuzumaki, N., Yokosawa, N., Yamagiwa, S., Iizuka, S., Makita, A., Sekiya, C. J. Natl. Cancer Inst. (1985) [Pubmed]
  4. Overview from the International Conference on Long-Term Tamoxifen Therapy for Breast Cancer. Jordan, V.C. J. Natl. Cancer Inst. (1992) [Pubmed]
  5. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lindstedt, S., Holme, E., Lock, E.A., Hjalmarson, O., Strandvik, B. Lancet (1992) [Pubmed]
  6. Incidence and risk factors for hepatocellular carcinoma in 967 patients with cirrhosis. del Olmo, J.A., Serra, M.A., Rodríguez, F., Escudero, A., Gilabert, S., Rodrigo, J.M. J. Cancer Res. Clin. Oncol. (1998) [Pubmed]
  7. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Maeda, S., Kamata, H., Luo, J.L., Leffert, H., Karin, M. Cell (2005) [Pubmed]
  8. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Grompe, M., Lindstedt, S., al-Dhalimy, M., Kennaway, N.G., Papaconstantinou, J., Torres-Ramos, C.A., Ou, C.N., Finegold, M. Nat. Genet. (1995) [Pubmed]
  9. Functional inactivation but not structural mutation of p53 causes liver cancer. Ueda, H., Ullrich, S.J., Gangemi, J.D., Kappel, C.A., Ngo, L., Feitelson, M.A., Jay, G. Nat. Genet. (1995) [Pubmed]
  10. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K., Fujimoto, I., Inoue, A., Yamazaki, H. N. Engl. J. Med. (1993) [Pubmed]
  11. Liver tumors induced in rats by oral administration of the antihistaminic methapyrilene hydrochloride. Lijinsky, W., Reuber, M.D., Blackwell, B.N. Science (1980) [Pubmed]
  12. Abnormal aminopyrine metabolism in patients with hepatic neoplasm. Detection by breath test. Hepner, G.W., Uhlin, S.R., Lipton, A., Harvey, H.A., Rohrer, V. JAMA (1976) [Pubmed]
  13. Thorium dioxide and liver cancer. Farid, I. JAMA (1982) [Pubmed]
  14. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Fisher, B., Costantino, J.P., Wickerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W.M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., Wolmark, N. J. Natl. Cancer Inst. (1998) [Pubmed]
  15. Survey of thorotrast-associated liver cancers in Japan. Yamada, S., Hosoda, S., Tateno, H., Kido, C., Takahashi, S. J. Natl. Cancer Inst. (1983) [Pubmed]
  16. Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Calvisi, D.F., Factor, V.M., Ladu, S., Conner, E.A., Thorgeirsson, S.S. Gastroenterology (2004) [Pubmed]
  17. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Leung, T.H., Ching, Y.P., Yam, J.W., Wong, C.M., Yau, T.O., Jin, D.Y., Ng, I.O. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  18. Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. Ino, Y., Gotoh, M., Sakamoto, M., Tsukagoshi, K., Hirohashi, S. Proc. Natl. Acad. Sci. U.S.A. (2002) [Pubmed]
  19. Reduced expression of glutathione S-transferase Yb2 during progression of chemically induced hepatocellular carcinomas in Fischer 344 rats. Stalker, M.J., Kocal, T.E., Quinn, B.A., Gordon, S.G., Hayes, M.A. Hepatology (1994) [Pubmed]
  20. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Wong, C.M., Yam, J.W., Ching, Y.P., Yau, T.O., Leung, T.H., Jin, D.Y., Ng, I.O. Cancer Res. (2005) [Pubmed]
  21. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Elmberg, M., Hultcrantz, R., Ekbom, A., Brandt, L., Olsson, S., Olsson, R., Lindgren, S., Lööf, L., Stål, P., Wallerstedt, S., Almer, S., Sandberg-Gertzén, H., Askling, J. Gastroenterology (2003) [Pubmed]
  22. Cycloprodigiosin hydrochloride, a new H(+)/Cl(-) symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Yamamoto, C., Takemoto, H., Kuno, K., Yamamoto, D., Tsubura, A., Kamata, K., Hirata, H., Yamamoto, A., Kano, H., Seki, T., Inoue, K. Hepatology (1999) [Pubmed]
  23. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cariani, E., Lasserre, C., Seurin, D., Hamelin, B., Kemeny, F., Franco, D., Czech, M.P., Ullrich, A., Brechot, C. Cancer Res. (1988) [Pubmed]
  24. Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. Olsen, J.H., Schulgen, G., Boice, J.D., Whysner, J., Travis, L.B., Williams, G.M., Johnson, F.B., McGee, J.O. Cancer Res. (1995) [Pubmed]
  25. CEACAM1, a cell-cell adhesion molecule, directly associates with annexin II in a three-dimensional model of mammary morphogenesis. Kirshner, J., Schumann, D., Shively, J.E. J. Biol. Chem. (2003) [Pubmed]
  26. Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. Hu, J., McCall, C.M., Ohta, T., Xiong, Y. Nat. Cell Biol. (2004) [Pubmed]
  27. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Tan, X., Apte, U., Micsenyi, A., Kotsagrelos, E., Luo, J.H., Ranganathan, S., Monga, D.K., Bell, A., Michalopoulos, G.K., Monga, S.P. Gastroenterology (2005) [Pubmed]
  28. Differential effect of thioacetamide on hepatic methionine adenosyltransferase expression in the rat. Huang, Z.Z., Mato, J.M., Kanel, G., Lu, S.C. Hepatology (1999) [Pubmed]
  29. Genotypic and phenotypic characterization of a putative tumor susceptibility gene, GNMT, in liver cancer. Tseng, T.L., Shih, Y.P., Huang, Y.C., Wang, C.K., Chen, P.H., Chang, J.G., Yeh, K.T., Chen, Y.M., Buetow, K.H. Cancer Res. (2003) [Pubmed]
  30. ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. Le Pabic, H., Bonnier, D., Wewer, U.M., Coutand, A., Musso, O., Baffet, G., Clément, B., Théret, N. Hepatology (2003) [Pubmed]
  31. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. Kaklamani, E., Trichopoulos, D., Tzonou, A., Zavitsanos, X., Koumantaki, Y., Hatzakis, A., Hsieh, C.C., Hatziyannis, S. JAMA (1991) [Pubmed]
  32. Hepatocellular carcinoma: diagnosis and treatment. Befeler, A.S., Di Bisceglie, A.M. Gastroenterology (2002) [Pubmed]
  33. Overexpression of glutamine synthetase in human primary liver cancer. Christa, L., Simon, M.T., Flinois, J.P., Gebhardt, R., Brechot, C., Lasserre, C. Gastroenterology (1994) [Pubmed]
  34. Promotion of liver cancer development by brief exposure to dietary 2-acetylaminofluorene plus partial hepatectomy or carbon tetrachloride. Solt, D.B., Cayama, E., Tsuda, H., Enomoto, K., Lee, G., Farber, E. Cancer Res. (1983) [Pubmed]
WikiGenes - Universities